Impact of early in-hospital initiation of sacubitril/valsartan on left ventricular reverse remodelling in acute heart failure
Early Sac/Val initiation after hospitalization for AHF may significantly improve LV function and morphology at 8 weeks, particularly in patients with an LVEF < 40%, supporting its role in LV reverse remodelling.
Authors
- Keisuke Kida (ORCID: https://orcid.org/0000-0002-3464-6016)
- Kei Mizukoshi (ORCID: https://orcid.org/0000-0003-1879-8818)
- Atsushi Tanaka (ORCID: https://orcid.org/0000-0003-3352-7661)
- Kenya Kusunose (ORCID: https://orcid.org/0000-0002-4909-754X)
- Yuya Matsue (ORCID: https://orcid.org/0000-0003-2456-8525)
- Toshiaki Kadokami (ORCID: https://orcid.org/0000-0001-9017-700X)
- Koichi Node (ORCID: https://orcid.org/0000-0002-2534-0939)
- Yutaka Furukawa (ORCID: https://orcid.org/0000-0003-4585-2437)
- Takumi Imai (ORCID: https://orcid.org/0000-0002-0541-3467)
- T Takahashi (ORCID: https://orcid.org/0000-0003-0805-0152)
- Taiji Okada (ORCID: https://orcid.org/0000-0002-8878-3446)
- Yumiko Kanzaki (ORCID: https://orcid.org/0000-0003-1228-1201)
- Hisao Matsuda
- Masataka Sata
Institutions
- St. Marianna University School of Medicine (JP)
- Saga University (JP)
- University of the Ryukyus (JP)
- Juntendo University (JP)
- Kobe University Hospital (JP)
- Yokohama City Seibu Hospital (JP)
- Clinical Research Organization (BD)
- Fukui-ken Saiseikai Hospital (JP)
- Tokushima University Hospital (JP)
- Japan Clinical Cancer Research Organization (JP)
- Kobe City Medical Center General Hospital (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- European Heart Journal - Cardiovascular Pharmacotherapy
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1093/ehjcvp/pvaf061
- Citations
- 3
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Novartis Pharma